Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study.

Carral N, Lukas JC, Oteo I, Suarez E.

Int J Antimicrob Agents. 2015 Jan;45(1):79-83. doi: 10.1016/j.ijantimicag.2014.08.011. Epub 2014 Oct 5.

PMID:
25450804
2.

Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.

Blondeau JM, Vaughan D, Laskowski R, Borsos S; Canadian Antimicrobial Study Group.

Int J Antimicrob Agents. 2001 Jun;17(6):457-64.

PMID:
11397615
3.

Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens.

Kiffer CR, Pignatari AC.

BMC Infect Dis. 2011 Oct 25;11:286. doi: 10.1186/1471-2334-11-286.

4.

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.

Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN; Alexander Project Group.

J Antimicrob Chemother. 2003 Aug;52(2):229-46. Epub 2003 Jul 15.

PMID:
12865398
6.

Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).

Jacobs E, Dalhoff A, Korfmann G.

Int J Antimicrob Agents. 2009 Jan;33(1):52-7. doi: 10.1016/j.ijantimicag.2008.07.017. Epub 2008 Oct 1.

PMID:
18835763
7.

[Study of pharmacokinetics/pharmacodynamics of levofloxacin].

Zhang J, Yu JC, Shi YG, Zhou L, Ye XY, Zhu DM, Zhang YY.

Zhonghua Yi Xue Za Zhi. 2005 Jul 20;85(27):1926-32. Chinese.

PMID:
16255991
9.

In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.

Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y.

Diagn Microbiol Infect Dis. 2012 Jun;73(2):187-91. doi: 10.1016/j.diagmicrobio.2012.03.005. Epub 2012 Apr 21.

PMID:
22521692
10.

[Bacterial resistance and pharmacodynamics as the basis for prescribing antibiotics in respiratory infections].

Aguado-García JM, Martín-Herrero JE, Lumbreras-Bermejo C.

Enferm Infecc Microbiol Clin. 2004 Apr;22(4):230-7. Review. Spanish.

PMID:
15056440
11.
12.

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.

Hermsen ED, Hovde LB, Konstantinides GN, Rotschafer JC.

Antimicrob Agents Chemother. 2005 Apr;49(4):1633-5.

14.

In vitro activity of fluoroquinolones against common respiratory pathogens.

Aydemir S, Tunger A, Cilli F.

West Indian Med J. 2006 Jan;55(1):9-12.

PMID:
16755812
16.
17.

Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.

Reed MD.

Postgrad Med. 2000 Dec;108(7 Suppl Contemporaty):17-24. doi: 10.3810/pgm.12.2000.suppl10.52. Review.

PMID:
19667545
19.

Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.

Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C.

Postgrad Med. 2008 Sep;120(3 Suppl 1):8-15. doi: 10.3810/pgm.2008.09.suppl52.279.

PMID:
18931466
20.

Supplemental Content

Support Center